Fundamental leadership · SEC EDGAR · no analyst estimates · as of 2026-07-20
Which industries lead on earnings and sales, today. As of 2026-07-20, 4,463 companies clear the eligibility gates and 1,339 rank Leader or Strong on filed EPS and revenue growth. The strongest industry group is Precious Metals with 29 Leader or Strong names. 19.4% of eligible companies also sit in the top relative-strength quintile — fundamentals and price agreeing.
Industry / Healthcare
| Ticker | Company | Rank | Δ3wk | Verdict | EPS YoY | Sales YoY | Margin Δ | 6M RS | Filed |
|---|---|---|---|---|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corporation Common Stock | 99 | ±0 | Leader | to profit↑ | >+999%↑ | — | 46 | 2026-05-13 |
| ORMP | Oramed Pharmaceuticals Inc. | 99 | ±0 | Leader | to profit | — | — | 68 | 2026-05-19 |
| PALI | Palisade Bio, Inc. Common Stock | 99 | ±0 | Leader | loss narrowed 89% | — | — | 66 | 2026-05-12 |
| QTTB | Q32 Bio Inc. Common Stock | 99 | ±0 | Leader | loss narrowed 40% | — | — | 99 | 2026-05-05 |
| SLGL | Sol-Gel Technologies Ltd. Ordinary Shares | 99 | ±0 | Leader | >+999% | +218% | — | 74 | 2026-03-19 |
| ZVRA | Zevra Therapeutics, Inc. Common Stock | 99 | +1 | Leader | to profit↑ | +78%↓ | >+10,000 bps | 86 | 2026-05-06 |
| BCRX | BioCryst Pharmaceuticals Inc | 98 | ±0 | Leader | to loss | +7% | -4970 bps | 82 | 2026-05-06 |
| CGEN | Compugen Ltd | 98 | ±0 | Leader | to profit | +161% | +9649 bps | 68 | 2026-03-02 |
| LKFT | Lakefront Biotherapeutics American Depositary Shares | 98 | ±0 | Leader | +335% | +304% | +9485 bps | — | 2026-03-26 |
| LQDA | Liquidia Corporation Common StockBiotech & Genomics | 98 | ±0 | Leader33 | to profit↑ | >+999%↑ | >+10,000 bps | 97 | 2026-05-11 |
| SPRO | Spero Therapeutics, Inc. Common Stock | 98 | ±0 | Leader | loss narrowed 48% | -100% | — | 17 | 2026-05-13 |
| TBPH | Theravance Biopharma, Inc. | 98 | ±0 | Leader | loss narrowed 63% | +15% | +7811 bps | 35 | 2026-05-07 |
| ANAB | AnaptysBio, Inc. Common Stock | 97 | ±0 | Leader | loss widened 44% | -8%↓ | >+10,000 bps | 65 | 2026-05-12 |
| ARQT | Arcutis Biotherapeutics, Inc. Common Stock | 97 | ±0 | Leader | loss narrowed 55% | +65%↓ | +5887 bps | 60 | 2026-05-06 |
| AUPH | Aurinia Pharmaceuticals Inc | 97 | ±0 | Leader | +56% | +24% | +2944 bps | 58 | 2026-05-07 |
| BEAM | Beam Therapeutics Inc. Common StockBiotech & Genomics | 97 | ±0 | Leader | loss narrowed 27% | +325%↑ | >+10,000 bps | 34 | 2026-05-07 |
| ETON | Eton Pharmaceutcials, Inc. Common Stock | 97 | ±0 | Leader | to profit | +40%↓ | +704 bps | 98 | 2026-05-14 |
| NBIX | Neurocrine Biosciences IncBiotech & Genomics | 97 | ±0 | Leader | >+999% | +42%↑ | +492 bps | 84 | 2026-05-05 |
| OMER | Omeros Corporation | 97 | ±0 | Leader | to profit | — | — | 30 | 2026-05-13 |
| RADX | Radiopharm Theranostics Limited American Depositary Shares | 97 | ±0 | Leader | loss narrowed 86% | >+999% | — | 34 | 2025-09-18 |
| TGTX | TG Therapeutics, Inc.Biotech & Genomics | 97 | ±0 | Leader | +300% | +70%↓ | +586 bps | 95 | 2026-05-06 |
| PLX | Protalix BioTherapeutics, Inc. Common Stock | 96 | ±0 | Leader | to profit | +234% | +1817 bps | 74 | 2026-05-13 |
| RANI | Rani Therapeutics Holdings, Inc. Class A Common Stock | 96 | +1 | Leader | loss narrowed 82% | +893%↑ | — | 12 | 2026-05-15 |
| RIGL | Rigel Pharmaceuticals Inc. (New) | 96 | ±0 | Leader | -30% | +10%↓ | +1993 bps | 61 | 2026-05-05 |
| XERS | Xeris Biopharma Holdings, Inc. Common Stock | 96 | ±0 | Leader | to profit | +38% | +2151 bps | 73 | 2026-05-07 |
| BMEA | Biomea Fusion, Inc. Common Stock | 95 | ±0 | Leader | loss narrowed 79% | — | — | 46 | 2026-05-11 |
| CRMD | CorMedix Inc. | 95 | +1 | Leader | +43% | +226% | — | 68 | 2026-05-14 |
| GTBP | GT Biopharma Inc. Common Stock | 95 | ±0 | Leader | loss narrowed 67% | — | — | 10 | 2026-05-15 |
| KNSA | Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares | 95 | ±0 | Leader | +145% | +56% | +1565 bps | 94 | 2026-04-28 |
| PMCB | PharmaCyte Biotech, Inc. Common Stock | 95 | ±0 | Leader | loss narrowed 61% | — | — | 21 | 2026-03-17 |
| ANIP | ANI Pharmaceuticals, Inc. | 94 | ±0 | Leader | +86% | +20%↓ | +1244 bps | 43 | 2026-05-08 |
| ARGX | argenx SE American Depositary Shares | 94 | ±0 | Leader | +53% | +254% | — | 60 | 2026-03-19 |
| ASMB | Assembly Biosciences, Inc | 94 | ±0 | Leader | loss narrowed 54% | -13% | — | 35 | 2026-05-07 |
| DTIL | Precision BioSciences, Inc. Common Stock | 94 | ±0 | Leader | loss narrowed 66% | >+999%↑ | -57 bps | 96 | 2026-05-05 |
| EVAX | Evaxion A/S American Depositary Share | 94 | ±0 | Leader | loss narrowed 90% | +125% | — | 18 | 2026-03-05 |
| EVMN | Evommune, Inc. | 94 | ±0 | Leader | loss narrowed 75% | +86% | — | 17 | 2026-05-07 |
| LGND | Ligand Pharmaceuticals Inc. | 94 | ±0 | Leader | loss narrowed 70%↓ | +14%↓ | +6852 bps | 91 | 2026-05-08 |
| LXRX | Lexicon Pharmaceuticals, Inc. | 94 | ±0 | Leader | to profit | >+999% | >+10,000 bps | 96 | 2026-05-07 |
| PRTA | Prothena Corporation plc Ordinary Shares | 94 | ±0 | Leader | to profit↑ | >+999% | <-10,000 bps | 46 | 2026-05-07 |
| ALVO | Alvotech Ordinary Shares | 93 | ±0 | Leader | to profit | +20% | -88 bps | 23 | 2026-03-31 |
| FDMT | 4D Molecular Therapeutics, Inc. Common Stock | 93 | ±0 | Leader | loss widened 17% | >+999% | — | 90 | 2026-05-07 |
| LLY | Eli Lilly & Co.GLP-1 / Obesity | 93 | ±0 | Leader | +170% | +56% | +1533 bps | 68 | 2026-04-30 |
| ONC | BeOne Medicines Ltd. American Depositary Shares | 93 | ±0 | Leader | to profit↓ | +35% | +1903 bps | 44 | 2026-05-06 |
| ADAG | Adagene Inc. American Depositary Shares | 92 | ±0 | Leader | loss narrowed 49% | >+999% | — | 96 | 2026-04-01 |
| ALNY | Alnylam Pharmaceuticals, Inc.Biotech & Genomics | 92 | ±0 | Leader | loss narrowed 73%↑ | +85% | +2137 bps | 28 | 2026-04-30 |
| JAGX | Jaguar Health, Inc. | 92 | ±0 | Leader | loss narrowed 19% | +816% | >+10,000 bps | 2 | 2026-05-20 |
| PHAT | Phathom Pharmaceuticals, Inc. Common Stock | 92 | ±0 | Leader | loss narrowed 72% | +104% | >+10,000 bps | 24 | 2026-04-30 |
| SCYX | SCYNEXIS, Inc. | 92 | ±0 | Leader | loss widened 282% | -100% | — | 28 | 2026-05-11 |
| TARS | Tarsus Pharmaceuticals, Inc. Common Stock | 92 | ±0 | Leader | loss narrowed 75%↑ | +107%↓ | +3722 bps | 29 | 2026-05-06 |
| TVTX | Travere Therapeutics, Inc. Common Stock | 92 | ±0 | Leader | loss narrowed 15%↓ | +56%↓ | +7244 bps | 96 | 2026-05-04 |
| AGEN | Agenus Inc. | 91 | ±0 | Leader | to profit | +40%↑ | >+10,000 bps | 86 | 2026-05-11 |
| ALGS | Aligos Therapeutics, Inc. Common Stock | 91 | ±0 | Leader | loss widened 5% | +810% | — | 19 | 2026-05-07 |
| ATHE | Alterity Therapeutics Limited American Depositary Shares | 91 | +1 | Leader | loss narrowed 63% | +89% | — | 89 | 2025-08-29 |
| INDV | Indivior Pharmaceuticals, Inc. Common Stock | 91 | ±0 | Leader | +82% | +19% | +2385 bps | 76 | 2026-04-30 |
| MGTX | MeiraGTx Holdings plc Ordinary Shares | 91 | ±0 | Leader | loss widened 12% | -85% | >+10,000 bps | 93 | 2026-05-14 |
| RLYB | Rallybio Corporation Common Stock | 91 | +41 | Leader | loss narrowed 14%↓ | 0% | — | 99 | 2026-05-13 |
| RXRX | Recursion Pharmaceuticals, Inc. Class A Common Stock | 91 | ±0 | Leader | loss narrowed 56% | -56% | +7876 bps | 18 | 2026-05-06 |
| BGMS | Bio Green Med Solution, Inc. Common Stock | 90 | ±0 | Leader | loss narrowed 100% | — | — | 19 | 2026-05-15 |
| INVA | Innoviva, Inc. Common Stock | 90 | ±0 | Leader | to profit↓ | +11% | -1120 bps | 64 | 2026-05-06 |
| PAHC | Phibro Animal Health Corporation Class A | 90 | ±0 | Leader | +16% | +10%↓ | +400 bps | 34 | 2026-05-06 |
| FBIO | Fortress Biotech, Inc. | 89 | ±0 | Strong | to profit | +21% | +8710 bps | 48 | 2026-05-14 |
| QUCY | Quantum Cyber N.V. Ordinary Shares | 89 | ±0 | Strong | loss narrowed 71% | +141%↑ | — | — | 2026-05-15 |
| ADCT | ADC Therapeutics SA | 88 | ±0 | Strong | loss narrowed 42% | +15% | +3746 bps | 7 | 2026-05-04 |
| COLL | Collegium Pharmaceutical, Inc. Common Stock | 88 | ±0 | Strong | +471% | +9%↓ | +232 bps | 28 | 2026-05-07 |
| PHAR | Pharming Group N.V. ADS, each representing 10 ordinary shares | 88 | ±0 | Strong | to profit | +27% | +977 bps | 25 | 2026-04-02 |
| PRME | Prime Medicine, Inc. Common Stock | 88 | ±0 | Strong | loss narrowed 30%↑ | -62%↓ | — | 29 | 2026-05-07 |
| RNXT | RenovoRx, Inc. Common Stock | 88 | ±0 | Strong | loss narrowed 20% | >+999% | — | 35 | 2026-05-14 |
| URGN | UroGen Pharma Ltd. Ordinary SharesBiotech & Genomics | 88 | ±0 | Strong33 | loss narrowed 49%↑ | +152%↑ | +4049 bps | 97 | 2026-05-06 |
| ASND | Ascendis Pharma A/S Ordinary Share | 87 | ±0 | Strong | loss narrowed 10%↓ | +42%↓ | +5774 bps | 74 | 2026-02-11 |
| BCYC | Bicycle Therapeutics plc American Depositary Shares | 87 | ±0 | Strong | loss narrowed 1% | -91% | >+10,000 bps | 20 | 2026-04-30 |
| FTLF | FitLife Brands, Inc. Common Stock | 87 | ±0 | Strong | -15% | +59% | -869 bps | 24 | 2026-05-14 |
| SNTI | Senti Biosciences Holdings, Inc. Common Stock | 87 | +1 | Strong | loss narrowed 90% | — | — | 9 | 2026-05-14 |
| ABBV | ABBVIE INC. | 86 | ±0 | Strong | -46% | +12%↑ | — | 74 | 2026-05-08 |
| ADPT | Adaptive Biotechnologies Corporation Common Stock | 86 | ±0 | Strong | loss narrowed 35%↓ | +35%↓ | +5984 bps | 79 | 2026-05-05 |
| ALT | Altimmune, Inc. Common StockGLP-1 / Obesity | 86 | ±0 | Strong | loss narrowed 31% | +420% | — | 21 | 2026-05-13 |
| IMCR | Immunocore Holdings plc American Depositary Shares | 86 | ±0 | Strong | +150%↑ | +14%↓ | +592 bps | 60 | 2026-05-06 |
| IVVD | Invivyd, Inc. Common Stock | 86 | ±0 | Strong | loss narrowed 7% | +22%↓ | >+10,000 bps | 6 | 2026-05-14 |
| KRYS | Krystal Biotech, Inc. Common Stock | 86 | ±0 | Strong | +53% | +32%↑ | +1029 bps | 77 | 2026-05-04 |
| SNDX | Syndax Pharmaceuticals, Inc. | 86 | ±0 | Strong | loss narrowed 51% | +224% | >+10,000 bps | 64 | 2026-04-30 |
| ADMA | ADMA Biologics, Inc. | 85 | ±0 | Strong | +73% | 0% | +904 bps | 12 | 2026-05-06 |
| DARE | Dare Bioscience, Inc. Common Stock | 85 | ±0 | Strong | loss narrowed 58% | +500% | — | 23 | 2026-05-14 |
| LNTH | Lantheus Holdings, Inc | 85 | ±0 | Strong | +76% | +1% | -1068 bps | 93 | 2026-05-07 |
| MREO | Mereo BioPharma Group plc American Depositary Shares | 85 | +1 | Strong | loss narrowed 50% | — | — | 10 | 2026-05-12 |
| NRXP | NRX Pharmaceuticals, Inc. Common Stock | 85 | ±0 | Strong | loss narrowed 88% | — | — | 96 | 2026-05-15 |
| STTK | Shattuck Labs, Inc. Common Stock | 85 | ±0 | Strong | loss narrowed 52% | — | — | 92 | 2026-05-07 |
| TCRX | TScan Therapeutics, Inc. Common Stock | 85 | ±0 | Strong | loss narrowed 15% | -55% | — | 32 | 2026-05-06 |
| VCEL | Vericel Corporation | 85 | ±0 | Strong | loss narrowed 48% | +30%↑ | +658 bps | 76 | 2026-05-07 |
| AMRX | Amneal Pharmaceuticals, Inc. Class A Common Stock | 84 | ±0 | Strong | +375%↑ | +4%↓ | +156 bps | 85 | 2026-05-07 |
| AXSM | Axsome Therapeutics, Inc | 84 | -1 | Strong | loss widened 3% | +57% | +3809 bps | 82 | 2026-05-04 |
| ENSC | Ensysce Biosciences, Inc. Common Stock | 84 | ±0 | Strong | loss narrowed 63% | -27% | — | 6 | 2026-05-15 |
| IOVA | Iovance Biotherapeutics, Inc. Common Stock | 84 | ±0 | Strong33 | loss narrowed 47%↑ | +45%↑ | +6034 bps | 97 | 2026-05-07 |
| JAZZ | Jazz Pharmaceuticals, Inc. | 84 | ±0 | Strong | to profit | +19%↑ | -1548 bps | 89 | 2026-05-05 |
| PRLD | Prelude Therapeutics Incorporated | 84 | ±0 | Strong | loss narrowed 23% | +73% | — | 96 | 2026-05-12 |
| BHST | BioHarvest Sciences Inc. Common Stock | 83 | ±0 | Strong | loss narrowed 25% | +37% | +1159 bps | 13 | 2026-03-31 |
| COCP | Cocrystal Pharma, Inc. Common Stock | 83 | ±0 | Strong | loss narrowed 26%↓ | — | — | 35 | 2026-05-15 |
| EOLS | Evolus, Inc. Common Stock | 83 | ±0 | Strong | loss narrowed 47% | +7% | +670 bps | 68 | 2026-05-04 |
| GERN | Geron Corp | 83 | ±0 | Strong | loss narrowed 67% | +31%↓ | — | 68 | 2026-05-06 |
| NATR | Nature's Sunshine Products Inc. | 83 | ±0 | Strong | +16% | +9% | +100 bps | 45 | 2026-05-07 |
| ORGO | Organogenesis Holdings Inc. Class A Common Stock | 83 | ±0 | Strong | loss widened 159% | -57% | +577 bps | 21 | 2026-05-07 |
| PHIO | Phio Pharmaceuticals Corp. Common Stock | 83 | ±0 | Strong | loss narrowed 17% | — | — | 48 | 2026-05-07 |
| VIVS | VivoSim Labs, Inc. Common Stock | 82 | +3 | Strong | to profit | +121%↑ | — | 5 | new filing |
| ARWR | Arrowhead Research CorporationGLP-1 / Obesity | 81 | ±0 | Strong | to loss | -86%↓ | -1393 bps | 65 | 2026-05-07 |
| BBIO | BridgeBio Pharma, Inc. Common Stock | 81 | ±0 | Strong | loss narrowed 5% | +67%↓ | >+10,000 bps | 62 | 2026-05-07 |
| DYAI | Dyadic International, Inc. | 81 | -1 | Strong | loss narrowed 29%↑ | +182%↑ | — | 87 | 2026-05-13 |
| OCS | Oculis Holding AG Ordinary shares | 81 | ±0 | Strong | loss narrowed 11% | +75% | — | 11 | 2026-03-04 |
| BCDA | BioCardia, Inc. Common Stock | 80 | ±0 | Strong | loss narrowed 64% | — | — | 20 | 2026-05-15 |
| PLRX | Pliant Therapeutics, Inc. Common Stock | 80 | ±0 | Strong | loss narrowed 65%↑ | — | — | 35 | 2026-05-11 |
| CBIO | Crescent Biopharma, Inc. Common Stock | 79 | ±0 | Strong | loss narrowed 76%↑ | — | — | 77 | 2026-04-29 |
| HYFT | MindWalk Holdings Corp. Common Stock | 79 | ±0 | Strong | loss narrowed 88%↑ | -32% | — | 25 | 2026-03-12 |
| NTLA | Intellia Therapeutics, IncBiotech & Genomics | 79 | ±0 | Strong | loss narrowed 26% | -9% | >+10,000 bps | 44 | 2026-05-11 |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | 79 | ±0 | Strong | +72% | +2% | +1059 bps | 48 | 2026-04-29 |
| CLLS | Cellectis S.A. American Depositary Shares | 78 | ±0 | Strong | loss narrowed 14% | +107% | — | 19 | 2026-03-20 |
| CRBU | Caribou Biosciences, Inc. Common Stock | 78 | ±0 | Strong | loss narrowed 40%↑ | +2% | — | 59 | 2026-05-07 |
| INM | InMed Pharmaceuticals Inc. Common Shares | 78 | ±0 | Strong | loss narrowed 86% | -26%↓ | — | 89 | 2026-05-06 |
| RFL | Rafael Holdings, Inc. Class B Common Stock | 78 | ±0 | Strong | loss narrowed 58% | -51% | — | 95 | 2026-06-11 |
| INMB | INmune Bio Inc. Common stock | 77 | ±0 | Strong | loss narrowed 53% | — | — | 79 | 2026-05-07 |
| MGNX | MacroGenics, Inc. | 77 | ±0 | Strong | loss narrowed 11%↑ | +57% | +2403 bps | 98 | 2026-05-13 |
| NUVB | Nuvation Bio Inc. | 77 | ±0 | Strong | to profit | >+999% | >+10,000 bps | 57 | 2026-05-04 |
| VTGN | Vistagen Therapeutics, Inc. Common Stock | 77 | ±0 | Strong | loss narrowed 16%↑ | — | — | 7 | 2026-06-15 |
| AVIR | Atea Pharmaceuticals, Inc. Common Stock | 76 | ±0 | Strong | loss narrowed 3% | +622% | — | 88 | 2026-05-12 |
| EXEL | Exelixis IncBiotech & Genomics | 76 | ±0 | Strong | +44% | +10% | +628 bps | 79 | 2026-05-05 |
| HOWL | Werewolf Therapeutics, Inc. Common Stock | 76 | +1 | Strong | loss narrowed 30% | — | — | 21 | 2026-05-07 |
| MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | 76 | ±0 | Strong | loss narrowed 2%↑ | +127%↓ | >+10,000 bps | 64 | 2026-05-06 |
| MRKR | Marker Therapeutics, Inc. Common Stock | 76 | ±0 | Strong | loss narrowed 60% | +115% | — | 26 | 2026-05-15 |
| QGEN | QIAGEN N.V. | 76 | ±0 | Strong | +424% | +6% | +1735 bps | 35 | 2026-03-20 |
| XFOR | X4 Pharmaceuticals, Inc. Common Stock | 76 | ±0 | Strong | to loss | -91%↓ | — | 56 | 2026-05-06 |
| ABCL | AbCellera Biologics Inc. Common SharesBiotech & Genomics | 75 | ±0 | Strong | loss narrowed 7% | +96% | >+10,000 bps | 88 | 2026-05-11 |
| ALLO | Allogene Therapeutics, Inc. Common Stock | 75 | ±0 | Strong | loss narrowed 36%↓ | — | — | 67 | 2026-05-13 |
| BMY | Bristol-Myers Squibb Co. | 75 | ±0 | Strong | +9% | +3% | +697 bps | 62 | 2026-04-30 |
| COYA | Coya Therapeutics, Inc. Common Stock | 75 | ±0 | Strong | loss narrowed 27% | -3%↓ | — | 67 | 2026-05-12 |
| CRON | Cronos Group Inc. Common Share | 75 | ±0 | Strong | +100% | +40% | +4239 bps | 65 | 2026-05-11 |
| INSM | Insmed, Inc.Biotech & Genomics | 75 | ±0 | Strong33 | loss narrowed 46%↑ | +230%↑ | >+10,000 bps | 22 | 2026-05-07 |
| VRDN | Viridian Therapeutics, Inc. Common Stock | 75 | ±0 | Strong | loss widened 35%↓ | +96% | — | 15 | 2026-05-05 |
| IRWD | Ironwood Pharmaceuticals, Inc. - Class A | 74 | ±0 | Strong | to profit | +159% | +3869 bps | 37 | 2026-05-07 |
| RYTM | Rhythm Pharmaceuticals, Inc. Common StockBiotech & Genomics | 74 | ±0 | Strong | loss widened 2%↑ | +84% | +3524 bps | 51 | 2026-05-05 |
| ACIU | AC Immune SA | 73 | +1 | Strong | loss narrowed 9% | +90% | — | 18 | 2026-03-13 |
| IXHL | Incannex Healthcare Limited American Depositary Shares | 73 | ±0 | Strong | loss widened 17% | +617% | — | 6 | 2026-05-15 |
| KTTA | Pasithea Therapeutics Corp. Common Stock | 73 | ±0 | Strong | loss narrowed 77% | >+999% | — | 13 | 2026-05-15 |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | 73 | ±0 | Strong | loss narrowed 35%↑ | — | — | 16 | 2026-05-13 |
| QURE | uniQure N.V.Biotech & Genomics | 73 | ±0 | Strong | loss widened 4% | +127% | <-10,000 bps | 96 | 2026-05-05 |
| RGEN | Repligen Corp | 73 | ±0 | Strong | +50%↓ | +15%↓ | +1342 bps | 42 | 2026-05-06 |
| RNTX | Rein Therapeutics, Inc. Common Stock | 73 | ±0 | Strong | loss narrowed 24% | — | — | 26 | 2026-05-15 |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | 73 | ±0 | Strong | +22%↑ | +11% | -1886 bps | 90 | 2026-05-06 |
| SNDL | Sundial Growers Inc. Common Shares | 73 | ±0 | Strong | loss narrowed 83% | +3% | +1001 bps | 30 | 2026-03-12 |
| AQST | Aquestive Therapeutics, Inc. Common Stock | 72 | ±0 | Strong | loss narrowed 71% | +66%↑ | -3524 bps | 75 | 2026-05-13 |
| AZN | AstraZeneca PLC | 72 | ±0 | Strong | +27% | +12% | — | 95 | 2026-02-24 |
| SLS | SELLAS Life Sciences Group, Inc. Common Stock | 72 | +1 | Strong | loss narrowed 29% | — | — | 99 | 2026-05-12 |
| AMGN | Amgen IncGLP-1 / Obesity | 71 | ±0 | Strong | +4% | +6%↓ | +658 bps | 67 | 2026-05-01 |
| IFRX | InflaRx N.V. Common Stock | 71 | ±0 | Strong | loss narrowed 13%↑ | +520% | — | 96 | 2026-03-20 |
| PRQR | ProQR Therapeutics N.V. Ordinary Shares | 71 | ±0 | Strong | loss narrowed 20%↑ | +9%↑ | <-10,000 bps | 69 | 2026-03-12 |
| SEPN | Septerna, Inc. Common Stock | 71 | ±0 | Strong | loss narrowed 61% | >+999% | — | 75 | 2026-05-11 |
| VIR | Vir Biotechnology, Inc. Common Stock | 71 | ±0 | Strong | loss narrowed 3% | -101% | >+10,000 bps | 91 | 2026-05-07 |
| XBIO | Xenetic Biosciences, Inc. | 71 | ±0 | Strong | loss narrowed 66% | +36% | — | 80 | 2026-05-12 |
| FHTX | Foghorn Therapeutics Inc. Common Stock | 70 | ±0 | Strong | loss narrowed 3% | -45% | >+10,000 bps | 34 | 2026-05-07 |
| RCKT | Rocket Pharmaceuticals, Inc. Common Stock | 70 | ±0 | Strong | loss narrowed 25% | — | — | 44 | 2026-05-07 |
| BTAI | BioXcel Therapeutics, Inc. Common Stock | 69 | ±0 | Average | loss narrowed 64% | +23%↑ | — | 10 | 2026-05-15 |
| CYTK | Cytokinetics Inc. | 69 | ±0 | Strong | loss widened 23% | >+999% | >+10,000 bps | 81 | 2026-05-05 |
| PYXS | Pyxis Oncology, Inc. Common Stock | 69 | ±0 | Average | loss widened 6% | — | — | 79 | 2026-05-14 |
| VRTX | Vertex Pharmaceuticals IncBiotech & Genomics | 69 | ±0 | Strong | +61%↑ | +8%↓ | +4500 bps | 66 | 2026-05-05 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 68 | ±0 | Average | loss widened 18% | >+999% | — | 91 | 2026-05-07 |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | 68 | ±0 | Average | +123% | +4% | +1147 bps | 57 | 2026-07-10 |
| HCM | HUTCHMED (China) Limited American Depositary Shares | 68 | ±0 | Average | >+999% | -13% | -20 bps | 27 | 2026-03-05 |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 68 | -1 | Average | loss widened 3% | +183%↑ | >+10,000 bps | 23 | 2026-05-11 |
| TSHA | Taysha Gene Therapies, Inc. Common Stock | 68 | ±0 | Average | loss widened 50%↓ | -100% | — | 71 | 2026-05-06 |
| TWST | Twist Bioscience Corporation Common StockBiotech & Genomics | 68 | ±0 | Average | loss widened 8%↓ | +19%↑ | +2396 bps | 97 | 2026-05-04 |
| CYPH | Cypherpunk Technologies Inc. Common Stock | 67 | ±0 | Average | loss widened 24% | 0% | — | 20 | 2026-05-14 |
| GOSS | Gossamer Bio, Inc. Common Stock | 67 | ±0 | Average | loss widened 25% | +71%↑ | <-10,000 bps | 2 | 2026-05-15 |
| IDXX | Idexx Laboratories Inc | 67 | ±0 | Average | +17%↓ | +14% | +248 bps | 31 | 2026-05-05 |
| NAGE | Niagen Bioscience, Inc. Common Stock | 67 | ±0 | Average | +17% | +3%↓ | -223 bps | 13 | 2026-05-06 |
| RLAY | Relay Therapeutics, Inc. Common Stock | 67 | ±0 | Average | loss narrowed 11%↓ | -61% | — | 98 | 2026-05-05 |
| SCNX | Scienture Holdings, Inc. Common Stock | 67 | ±0 | Average | loss narrowed 76%↓ | +449% | — | 31 | 2026-05-15 |
| SDGR | Schrodinger, Inc. Common Stock | 67 | ±0 | Average | loss narrowed 1% | -2%↓ | +1897 bps | 37 | 2026-05-05 |
| ZLAB | Zai Lab Limited American Depositary Shares | 67 | ±0 | Average | loss widened 25% | -10% | +1019 bps | 66 | 2026-05-07 |
| AGIO | Agios Pharmaceuticals, Inc. | 66 | ±0 | Average33 | loss widened 9%↑ | +138%↑ | >+10,000 bps | 90 | 2026-04-29 |
| ATYR | aTyr Pharma, Inc. Common Stock | 66 | ±0 | Average | loss narrowed 35%↑ | — | — | 23 | 2026-05-15 |
| BTMD | Biote Corp. Class A Common Stock | 66 | +1 | Average | -84% | -8%↓ | -6 bps | 60 | 2026-05-11 |
| CGON | CG Oncology, Inc. Common stock | 66 | ±0 | Average | loss widened 58% | >+999% | — | 85 | 2026-05-08 |
| VYGR | Voyager Therapeutics, Inc. Common Stock | 66 | +1 | Average | loss narrowed 11% | -60% | <-10,000 bps | 31 | 2026-05-07 |
| ENTA | Enanta Pharmaceuticals, Inc | 65 | ±0 | Average | loss narrowed 58% | +15% | +8353 bps | 51 | 2026-05-13 |
| GDTC | CytoMed Therapeutics Limited Ordinary Shares | 64 | ±0 | Average | loss widened 69% | +367% | — | 60 | 2026-03-31 |
| HROW | Harrow, Inc. Common Stock | 64 | ±0 | Average | loss widened 48%↓ | -8%↓ | +520 bps | 44 | 2026-05-11 |
| NNVC | NanoViricides Inc. | 64 | ±0 | Average | loss narrowed 36% | — | — | 92 | 2026-05-15 |
| MRNA | Moderna, Inc. Common StockBiotech & Genomics | 63 | ±0 | Average | loss widened 35% | +260%↑ | -3597 bps | 92 | 2026-05-01 |
| SBFM | Sunshine Biopharma Inc. | 62 | ±0 | Average | loss narrowed 43% | -9% | -194 bps | 3 | 2026-05-13 |
| WVE | Wave Life Sciences Ltd. Ordinary Shares | 62 | ±0 | Average | loss narrowed 55% | +317% | — | 9 | 2026-04-28 |
| ABVC | ABVC BioPharma, Inc. Common Stock | 61 | ±0 | Average | loss widened 0%↑ | >+999%↑ | — | 17 | 2026-05-18 |
| ACAD | Acadia Pharmaceuticals Inc. | 61 | ±0 | Average | -82%↓ | +10% | -1619 bps | 47 | 2026-05-07 |
| MTEX | Mannatech Inc. | 61 | ±0 | Average | to profit | -6%↑ | +197 bps | 14 | 2026-05-14 |
| OCGN | Ocugen, Inc. Common Stock | 61 | ±0 | Average | loss widened 20%↓ | +4% | — | 33 | 2026-05-08 |
| ANIX | Anixa Biosciences, Inc. | 60 | +31 | Average | loss narrowed 22% | — | — | 64 | 2026-06-10 |
| AUTL | Autolus Therapeutics plc American Depositary Share | 60 | ±0 | Average | loss widened 4% | +192%↓ | — | 49 | 2026-05-14 |
| HYPD | Hyperion DeFi, Inc. Common Stock | 60 | ±0 | Average | to profit | >+999%↓ | — | 33 | 2026-05-15 |
| IMMP | Immutep Limited American Depositary Shares | 60 | ±0 | Average | loss widened 19% | +32% | — | 3 | 2025-10-24 |
| KMDA | Kamada Ltd | 60 | ±0 | Average | 0%↓ | +13% | — | 38 | 2026-03-11 |
| RARE | Ultragenyx Pharmaceutical Inc.Biotech & Genomics | 60 | ±0 | Average | loss widened 17% | -2% | +317 bps | 78 | 2026-05-06 |
| SCNI | Scinai Immunotherapeutics Ltd. American Depositary Shares | 60 | ±0 | Average | to loss | >+999% | — | 5 | 2026-04-01 |
| BFRI | Biofrontera Inc. Common Stock | 59 | ±0 | Average | loss narrowed 13% | +17% | +1713 bps | 81 | 2026-05-14 |
| OTLK | Outlook Therapeutics, Inc. Common Stock | 59 | ±0 | Average | loss narrowed 97% | — | — | 98 | 2026-05-15 |
| IBRX | ImmunityBio, Inc. Common Stock | 58 | ±0 | Average | loss widened 313%↓ | +168%↓ | >+10,000 bps | 96 | 2026-05-07 |
| SILO | Silo Pharma, Inc. Common Stock | 58 | ±0 | Average | loss narrowed 48% | 0% | — | 34 | 2026-05-14 |
| GELS | Gelteq Limited Ordinary Shares | 57 | ±0 | Average | loss widened 64% | +107% | — | 11 | 2025-11-17 |
| GILD | Gilead Sciences Inc | 57 | ±0 | Average | +55% | +4% | +627 bps | 67 | 2026-05-07 |
| SXTP | 60 Degrees Pharmaceuticals, Inc. Common Stock | 57 | ±0 | Average | loss narrowed 18% | -1%↓ | — | 32 | 2026-05-15 |
| UTHR | United Therapeutics Corp | 57 | ±0 | Average | -12% | -2% | -159 bps | 70 | 2026-05-06 |
| CRDF | Cardiff Oncology, Inc. Common Stock | 56 | ±0 | Average | loss narrowed 10% | -62% | — | 6 | 2026-05-14 |
| CUE | Cue Biopharma, Inc. | 56 | ±0 | Average | loss widened 535% | >+999% | — | 99 | 2026-05-14 |
| PGEN | Precigen, Inc. Common Stock | 56 | ±0 | Average | loss narrowed 89%↑ | >+999% | — | 79 | 2026-05-13 |
| SPRY | ARS Pharmaceuticals, Inc. Common Stock | 56 | +1 | Average | loss widened 74% | +184% | <-10,000 bps | 16 | 2026-05-15 |
| ARDX | Ardelyx, Inc. | 55 | ±0 | Average | loss narrowed 12% | +27% | +220 bps | 25 | 2026-04-30 |
| BIOA | BioAge Labs, Inc. Common Stock | 55 | ±0 | Average | loss widened 44% | +91% | — | 59 | 2026-05-08 |
| CGC | Canopy Growth Corporation Common Shares | 55 | — | Average | loss narrowed 85%↓ | 0%↓ | >+10,000 bps | 29 | 2026-06-15 |
| HALO | Halozyme Therapeutics, Inc. | 55 | ±0 | Average | +31% | +42% | -2116 bps | 64 | 2026-05-11 |
| IONS | Ionis Pharmaceuticals, Inc. Common StockBiotech & Genomics | 55 | ±0 | Average | loss narrowed 40% | +87% | — | 23 | 2026-04-29 |
| LCTX | Lineage Cell Therapeutics, Inc. | 55 | ±0 | Average | loss widened 50%↑ | +15% | — | 21 | 2026-05-12 |
| MNOV | Medicinova, Inc. | 54 | ±0 | Average | loss narrowed 17% | — | — | 36 | 2026-05-14 |
| OGEN | Oragenics Inc. | 54 | ±0 | Average | loss widened 325% | — | — | 16 | 2026-05-08 |
| TKNO | Alpha Teknova, Inc. Common Stock | 54 | +1 | Average | loss narrowed 11% | +13% | +2144 bps | 89 | 2026-05-07 |
| NVO | Novo-Nordisk A/SGLP-1 / Obesity | 53 | ±0 | Average | +2% | +6% | -289 bps | 38 | 2026-02-04 |
| UPC | Universe Pharmaceuticals Inc. Class A Ordinary Shares | 53 | ±0 | Average | loss narrowed 99% | >+999% | +1850 bps | — | 2026-01-29 |
| ATAI | AtaiBeckley Inc. Common Stock | 52 | +1 | Average | loss widened 213% | >+999% | — | 96 | 2026-05-12 |
| IMCC | IM Cannabis Corp. Common Shares | 52 | ±0 | Average | loss narrowed 41% | +1% | -223 bps | 2 | 2026-03-30 |
| EQ | Equillium, Inc. Common Stock | 51 | ±0 | Average | loss narrowed 75% | -52%↓ | — | 98 | 2026-05-13 |
| HRMY | Harmony Biosciences Holdings, Inc. Common Stock | 51 | ±0 | Average | -29% | +17%↓ | -511 bps | 44 | 2026-05-07 |
| UPB | Upstream Bio, Inc. Common Stock | 51 | ±0 | Average | loss widened 47% | +83% | — | 4 | 2026-05-13 |
| FENC | Fennec Pharmaceuticals Inc. Common Stock | 50 | ±0 | Average | to profit | +73%↓ | +2780 bps | 86 | 2026-05-14 |
| KURA | Kura Oncology, Inc. | 50 | ±0 | Average | loss widened 57% | +25% | -9140 bps | 77 | 2026-05-12 |
| EDIT | Editas Medicine, Inc. Common Stock | 49 | +1 | Average | loss narrowed 72% | -39%↓ | >+10,000 bps | 87 | 2026-05-05 |
| PPBT | Purple Biotech Ltd. American Depositary Shares | 49 | +1 | Average | -99% | 0% | — | 4 | 2026-03-19 |
| TLX | Telix Pharmaceuticals Limited American Depositary Shares | 49 | +1 | Average | to loss | +56% | — | 89 | 2026-02-20 |
| TRLV | Trulieve Cannabis Corp. | 49 | +1 | Average | to profit | -4%↓ | +530 bps | — | 2026-05-07 |
| ACB | Aurora Cannabis Inc. Common Shares | 48 | ±0 | Average | -89% | +27% | +1863 bps | 18 | 2026-06-11 |
| PBH | Prestige Consumer Healthcare Inc. | 48 | ±0 | Average | +13%↑ | -5% | -118 bps | 29 | 2026-05-14 |
| PTGX | Protagonist Therapeutics, Inc | 48 | +1 | Average | to profit | +99% | <-10,000 bps | 93 | 2026-05-05 |
| VRCA | Verrica Pharmaceuticals Inc. Common Stock | 48 | ±0 | Average | loss widened 350% | +46%↓ | — | 25 | 2026-05-12 |
| HCWB | HCW Biologics Inc. Common Stock | 47 | +1 | Average | to profit | >+999%↑ | — | 15 | 2026-05-14 |
| JNJ | Johnson & Johnson | 47 | ±0 | Average | -53%↓ | +10%↑ | -747 bps | 71 | 2026-04-22 |
| NNNN | Anbio Biotechnology Class A Ordinary Shares | 47 | ±0 | Average | +163% | +6% | — | 5 | 2026-04-07 |
| PLUR | Pluri Inc. Common Stock | 47 | ±0 | Average | loss narrowed 41% | -61% | — | 15 | 2026-05-14 |
| SUPN | Supernus Pharmaceuticals, Inc. | 47 | ±0 | Average | loss narrowed 81%↑ | +39%↑ | -1893 bps | 47 | 2026-05-05 |
| DERM | Journey Medical Corporation Common Stock | 46 | ±0 | Average | loss narrowed 56% | +21% | +261 bps | 36 | 2026-05-13 |
| IPSC | Century Therapeutics, Inc. Common Stock | 45 | ±0 | Average | to loss | -100% | — | 47 | 2026-05-13 |
| LFCR | Lifecore Biomedical, Inc. Common Stock | 45 | ±0 | Average | loss narrowed 9% | -34% | +2533 bps | 16 | 2026-05-06 |
| MNKD | Mannkind Corporation | 45 | ±0 | Average | to loss | +15% | -2215 bps | 25 | 2026-05-06 |
| REGN | Regeneron Pharmaceuticals IncGLP-1 / Obesity | 45 | ±0 | Average | -7%↓ | +19%↑ | -287 bps | 42 | 2026-04-29 |
| ERNA | Ernexa Therapeutics Inc. Common Stock | 44 | ±0 | Average | loss widened 999%↓ | — | — | 4 | 2026-05-11 |
| SRZN | Surrozen, Inc. Common | 44 | ±0 | Average | loss widened 57%↑ | +409%↑ | — | 68 | 2026-05-06 |
| CYRX | CryoPort, Inc. Common Stock | 43 | +1 | Average | loss narrowed 11% | +16% | +3523 bps | 88 | 2026-05-05 |
| VNRX | VolitionRx Limited | 43 | ±0 | Average | loss widened 999%↓ | +300%↑ | — | 4 | 2026-05-14 |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | 42 | ±0 | Average | loss narrowed 90% | -45% | — | 4 | 2026-03-27 |
| IMDX | Insight Molecular Diagnostics Inc. Common Stock | 42 | +1 | Average | loss narrowed 54% | -99%↓ | — | 26 | 2026-05-13 |
| KALA | KALA BIO, Inc. Common Stock | 42 | ±0 | Average | loss narrowed 90% | -100%↓ | — | 1 | 2026-05-15 |
| AMRN | Amarin Corp Plc | 41 | ±0 | Average | loss narrowed 25% | +7% | +2371 bps | 43 | 2026-04-29 |
| IDYA | IDEAYA Biosciences, Inc. Common Stock | 41 | +1 | Average | loss widened 35%↓ | — | — | 51 | 2026-05-05 |
| TECH | Bio-Techne Corp. | 41 | ±0 | Average | +129% | -2% | -153 bps | 57 | 2026-05-06 |
| CCCC | C4 Therapeutics, Inc. | 40 | ±0 | Average | loss narrowed 46% | -15% | — | 93 | 2026-05-12 |
| CDIO | Cardio Diagnostics Holdings Inc. Common stock | 40 | +1 | Average | loss narrowed 35% | +185%↑ | — | 45 | 2026-05-15 |
| DBVT | DBV Technologies S.A. | 40 | -32 | Average | loss narrowed 61%↑ | -52%↓ | — | 29 | new filing |
| GANX | Gain Therapeutics, Inc. Common Stock | 40 | +1 | Average | loss narrowed 19% | — | — | 38 | 2026-05-11 |
| RDY | Dr. Reddy's Laboratories Limited American Depositary Shares | 40 | ±0 | Average | -80% | +17% | -219 bps | 48 | 2026-05-29 |
| SABS | SAB Biotherapeutics, Inc. Common Stock | 40 | ±0 | Average | loss narrowed 38% | -62% | — | 39 | 2026-05-12 |
| XLO | Xilio Therapeutics, Inc. Common Stock | 40 | ±0 | Average | loss widened 222% | +332% | — | 48 | 2026-05-12 |
| BLRX | BioLineRX Ltd | 39 | +1 | Average | to profit | -96% | — | 51 | 2026-03-23 |
| LEXX | Lexaria Bioscience Corp. Common Stock | 39 | +1 | Average | loss narrowed 62%↑ | -100% | — | 33 | new filing |
| MIRM | Mirum Pharmaceuticals, Inc. Common Stock | 39 | +1 | Average | loss widened 999%↓ | +43% | <-10,000 bps | 82 | 2026-05-06 |
| MNPR | Monopar Therapeutics Inc. Common Stock | 39 | +1 | Average | loss widened 21% | — | — | 92 | 2026-05-14 |
| BMRN | BioMarin Pharmaceuticals Inc | 38 | ±0 | Average | -43% | +3% | -1128 bps | 64 | 2026-05-05 |
| NVAX | Novavax Inc | 38 | ±0 | Average | to loss | -79% | -4589 bps | 55 | 2026-05-06 |
| ZTS | ZOETIS INC. | 38 | ±0 | Average | +1%↓ | +2% | +37 bps | 18 | 2026-05-07 |
| CRIS | Curis Inc | 37 | ±0 | Average | loss widened 0% | -100%↓ | — | 5 | 2026-05-13 |
| GYRE | Gyre Therapeutics, Inc. Common Stock | 37 | ±0 | Average | to loss | +2% | -1042 bps | 28 | 2026-05-08 |
| IBIO | iBio, Inc. Common Stock | 37 | +1 | Average | loss narrowed 88%↑ | — | — | 18 | 2026-05-12 |
| SNGX | Soligenix, Inc. Common Stock | 37 | ±0 | Average | loss narrowed 71% | -100% | — | 5 | 2026-05-08 |
| TVRD | Tvardi Therapeutics, Inc. Common Stock | 36 | ±0 | Average | loss narrowed 77% | +20% | — | 20 | 2026-05-08 |
| CHRS | Coherus Oncology, Inc. Common Stock | 34 | ±0 | Average | loss narrowed 43%↑ | +62%↑ | <-10,000 bps | 37 | 2026-05-11 |
| CORT | Corcept Therapeutics Inc.Biotech & Genomics | 34 | ±0 | Average | to loss | +5%↓ | -1724 bps | 98 | 2026-04-30 |
| LPCN | Lipocine Inc. | 34 | ±0 | Average | loss widened 54% | +27%↑ | — | 4 | 2026-05-07 |
| RMTI | Rockwell Medical, Inc. (DE) Common Stock | 34 | +1 | Average | loss widened 0% | -8%↑ | -769 bps | 21 | 2026-05-07 |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | 34 | ±0 | Average | -26% | +7% | +246 bps | 60 | 2026-06-17 |
| VYNE | VYNE Therapeutics Inc. Common Stock | 34 | ±0 | Average | loss narrowed 60%↑ | -57% | — | 89 | 2026-05-15 |
| APRE | Aprea Therapeutics, Inc. Common stock | 33 | ±0 | Average | loss narrowed 67%↑ | -98% | — | 27 | 2026-05-13 |
| DSGN | Design Therapeutics, Inc. Common Stock | 33 | ±0 | Average | loss narrowed 6%↑ | — | — | 82 | 2026-04-28 |
| GOVX | GeoVax Labs, Inc. New | 33 | ±0 | Average | loss widened 482% | -100% | — | 7 | 2026-05-14 |
| KZIA | Kazia Therapeutics Limited American Depositary Shares | 33 | ±0 | Average | loss narrowed 63% | -98% | — | 96 | 2025-11-07 |
| CSBR | Champions Oncology, Inc. | 32 | ±0 | Average | to loss | -3% | -1526 bps | 36 | 2026-03-12 |
| GNLX | Genelux Corporation Common Stock | 32 | ±0 | Average | loss narrowed 5%↑ | — | — | 72 | 2026-05-07 |
| ICCC | Immucell Corp | 32 | ±0 | Average | +31% | +28%↑ | +917 bps | 94 | 2026-05-14 |
| IMRX | Immuneering Corporation Class A Common Stock | 32 | ±0 | Average | loss narrowed 50% | -100% | — | 44 | 2026-05-15 |
| INO | Inovio Pharmaceuticals, Inc. | 32 | ±0 | Average | loss narrowed 45% | -100% | — | 23 | 2026-05-13 |
| PULM | Pulmatrix, Inc. Common Stock | 32 | +25 | Average | loss narrowed 36%↓ | -100%↓ | — | 21 | 2026-05-15 |
| VTRS | Viatris Inc. Common Stock | 32 | ±0 | Average33 | to profit↑ | +8%↑ | +2250 bps | 85 | 2026-05-07 |
| ACRS | Aclaris Therapeutics, Inc. | 30 | +1 | Average | loss widened 25% | +37% | — | 97 | 2026-05-07 |
| CRSP | CRISPR Therapeutics AGBiotech & Genomics | 30 | ±0 | Average | loss narrowed 19% | +69% | — | 38 | 2026-05-04 |
| ELUT | Elutia Inc. Class A Common Stock | 30 | ±0 | Average | loss narrowed 19% | -48%↓ | — | 71 | 2026-05-15 |
| IGC | IGC Pharma, Inc. | 30 | +1 | Average | loss widened 0% | -42% | — | 44 | 2026-05-15 |
| INBX | Inhibrx Biosciences, Inc. Common Stock | 30 | ±0 | Average | loss narrowed 23% | -100% | — | 74 | 2026-05-14 |
| TRAW | Traws Pharma, Inc. Common Stock | 30 | ±0 | Average | to loss | -100% | — | 7 | 2026-05-15 |
| ALXO | ALX Oncology Holdings Inc. Common Stock | 29 | +1 | Laggard | loss narrowed 71% | — | — | 93 | 2026-05-08 |
| ELOX | Eloxx Pharmaceuticals, Inc. Common Stock | 29 | ±0 | Laggard | loss narrowed 42% | -100% | — | — | 2026-05-05 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 28 | ±0 | Laggard | -73% | 0% | -1045 bps | 28 | 2026-05-07 |
| BNTC | Benitec Biopharma Inc. Common Stock | 28 | ±0 | Laggard | loss widened 0%↑ | — | — | 57 | 2026-05-14 |
| FATE | Fate Therapeutics, Inc. | 28 | ±0 | Laggard | loss narrowed 19% | -20%↑ | — | 98 | 2026-05-13 |
| GRCE | Grace Therapeutics, Inc. Common Stock | 28 | ±0 | Laggard | loss narrowed 41% | -100% | — | 21 | 2026-06-18 |
| PBYI | PUMA BIOTECHNOLOGY INC | 28 | ±0 | Laggard | to loss | -3% | -303 bps | 84 | 2026-05-07 |
| ACET | Adicet Bio, Inc. Common Stock | 27 | ±0 | Laggard | loss widened 506% | -100% | — | 52 | 2026-05-13 |
| ALKS | Alkermes Inc. plc | 27 | ±0 | Laggard | to loss↓ | +28% | -1356 bps | 94 | 2026-05-05 |
| LSTA | Lisata Therapeutics, Inc. Common Stock | 27 | +1 | Laggard | loss narrowed 9% | — | — | 94 | 2026-05-11 |
| ABT | Abbott Laboratories | 26 | ±0 | Laggard | -20% | +8% | +23 bps | 34 | 2026-04-29 |
| AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | 26 | ±0 | Laggard | loss narrowed 12%↓ | — | — | 84 | 2026-05-07 |
| ATNM | Actinium Pharmaceuticals, Inc | 26 | ±0 | Laggard | loss narrowed 65% | — | — | 22 | 2026-05-08 |
| ATRA | Atara Biotherapeutics, Inc | 26 | ±0 | Laggard | to loss↓ | -99%↓ | -2056 bps | 95 | 2026-05-12 |
| JANX | Janux Therapeutics, Inc. Common Stock | 26 | ±0 | Laggard | loss widened 3% | — | — | 74 | 2026-05-07 |
| TLRY | Tilray Brands, Inc. Common Stock | 26 | ±0 | Laggard | loss narrowed 72% | +11% | -6083 bps | 9 | 2026-04-01 |
| TXMD | TherapeuticsMD, Inc. | 26 | ±0 | Laggard | to profit | +84% | — | 46 | 2026-05-12 |
| ANVS | Annovis Bio, Inc. | 25 | ±0 | Laggard | loss widened 97%↓ | — | — | 13 | 2026-05-15 |
| ARMP | Armata Pharmaceuticals, Inc. Common Stock | 25 | ±0 | Laggard | loss widened 999% | +61%↑ | — | 31 | 2026-05-13 |
| CAMP | CAMP4 Therapeutics Corporation Common Stock | 25 | ±0 | Laggard | loss narrowed 48% | +51%↑ | — | 16 | 2026-05-07 |
| IKT | Inhibikase Therapeutics, Inc. Common Stock | 25 | ±0 | Laggard | loss narrowed 33% | — | — | 86 | 2026-05-12 |
| MBIO | Mustang Bio, Inc. | 25 | ±0 | Laggard | loss widened 180% | — | — | 18 | 2026-05-05 |
| MYGN | Myriad Genetics Inc | 25 | ±0 | Laggard | to loss | +2%↑ | -3192 bps | 50 | 2026-05-06 |
| PCRX | Pacira BioSciences, Inc. Common Stock | 25 | ±0 | Laggard | -30% | +5%↓ | +1532 bps | 79 | 2026-04-30 |
| SRRK | Scholar Rock Holding Corporation Common StockGLP-1 / Obesity | 25 | ±0 | Laggard | loss widened 24% | — | — | 65 | 2026-05-07 |
| ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | 25 | ±0 | Laggard | loss narrowed 25%↓ | -100% | — | 93 | 2026-05-12 |
| AKBA | Akebia Therapeutics, Inc. | 24 | ±0 | Laggard | to loss↓ | -7%↓ | +1419 bps | 48 | 2026-05-07 |
| GLAS | Glass House Brands Inc. | 24 | — | Laggard | loss widened 162% | -9% | -1194 bps | — | 2026-05-13 |
| KYMR | Kymera Therapeutics, Inc. Common StockBiotech & Genomics | 24 | ±0 | Laggard | loss narrowed 13%↑ | +55% | <-10,000 bps | 93 | 2026-04-30 |
| RCUS | Arcus Biosciences, Inc. | 24 | +1 | Laggard | loss narrowed 11% | -12% | — | 84 | 2026-05-05 |
| TLPH | Talphera, Inc. Common Stock | 24 | ±0 | Laggard | loss narrowed 60%↑ | -100% | — | 84 | 2026-05-13 |
| AKTX | Akari Therapeutics plc ADR (0.01 USD) | 23 | ±0 | Laggard | 0% | -39% | — | — | 2026-05-19 |
| MRK | Merck & Co., Inc.GLP-1 / Obesity | 23 | ±0 | Laggard | to loss↓ | +5% | -1387 bps | 70 | 2026-05-04 |
| MRVI | Maravai LifeSciences Holdings, Inc. Class A Common Stock | 23 | ±0 | Laggard | loss narrowed 90% | +41%↑ | +2776 bps | 96 | 2026-05-08 |
| NAII | Natural Alternatives International Inc. | 23 | ±0 | Laggard | loss widened 95%↓ | +23% | +206 bps | 10 | 2026-05-19 |
| TPST | Tempest Therapeutics, Inc. Common Stock | 23 | ±0 | Laggard | loss narrowed 20%↑ | -2% | — | 25 | 2026-05-14 |
| BHC | Bausch Health Companies Inc | 22 | ±0 | Laggard | loss widened 999%↓ | +12%↑ | -1026 bps | 20 | 2026-04-30 |
| IMNM | Immunome, Inc. | 22 | ±0 | Laggard | loss narrowed 8% | -100% | — | 49 | 2026-05-12 |
| SLDB | Solid Biosciences Inc. Common Stock | 22 | ±0 | Laggard | loss widened 24%↓ | -100% | — | 91 | 2026-05-12 |
| TNGX | Tango Therapeutics, Inc. | 22 | ±0 | Laggard | loss narrowed 11%↓ | -100% | >+10,000 bps | 98 | 2026-05-13 |
| XCUR | Exicure, Inc. Common Stock | 22 | ±0 | Laggard | to loss | — | — | 6 | 2026-05-29 |
| NEOG | Neogen Corp | 21 | ±0 | Laggard | loss widened 60%↓ | -4%↓ | +4050 bps | 62 | 2026-04-09 |
| SLN | Silence Therapeutics Plc American Depository Share | 21 | ±0 | Laggard | loss narrowed 45% | +197% | — | 96 | 2026-05-07 |
| ELAN | Elanco Animal Health Incorporated Common Stock | 20 | ±0 | Laggard | -15% | +15%↑ | -1613 bps | 60 | 2026-05-06 |
| ELTX | Elicio Therapeutics, Inc. Common Stock | 20 | ±0 | Laggard | loss narrowed 25% | -100% | — | 8 | 2026-05-11 |
| IPHA | Innate Pharma S.A. ADS | 20 | ±0 | Laggard | loss narrowed 10% | -78% | — | 51 | 2026-04-01 |
| OCUL | Ocular Therapeutix, Inc. | 20 | ±0 | Laggard | loss widened 5%↑ | +1% | <-10,000 bps | 29 | 2026-05-05 |
| USNA | USANA Health Sciences Inc | 20 | ±0 | Laggard | -16%↑ | 0%↓ | -269 bps | 59 | 2026-05-12 |
| BYSI | BeyondSpring Inc. Ordinary Shares | 19 | ±0 | Laggard | to loss↓ | — | — | 24 | 2026-05-13 |
| CMPX | Compass Therapeutics, Inc. Common Stock | 19 | ±0 | Laggard | loss narrowed 17% | — | — | 7 | 2026-05-05 |
| CPIX | Cumberland Pharmaceuticals Inc | 19 | ±0 | Laggard | to loss | -22% | -924 bps | 92 | 2026-05-08 |
| HUMA | Humacyte, Inc. Common Stock | 19 | +5 | Laggard | to loss↓ | -4% | — | 17 | 2026-05-13 |
| BIIB | Biogen Inc. Common Stock | 18 | ±0 | Laggard | +31% | +2% | -152 bps | 76 | 2026-04-29 |
| CPHI | China Pharma Holdings, Inc. | 18 | ±0 | Laggard | loss narrowed 83%↑ | -13% | — | 26 | 2026-05-15 |
| KPTI | Karyopharm Therapeutics Inc. | 18 | ±0 | Laggard | loss narrowed 55% | +17% | +2796 bps | 70 | 2026-05-14 |
| ABEO | Abeona Therapeutics Inc. Common Stock | 17 | ±0 | Laggard | loss widened 25% | — | — | 76 | 2026-05-13 |
| LRMR | Larimar Therapeutics, Inc. Common Stock | 17 | ±0 | Laggard | loss widened 154% | — | — | 75 | 2026-05-14 |
| CADL | Candel Therapeutics, Inc. Common Stock | 16 | ±0 | Laggard | to loss↓ | 0% | — | 93 | 2026-05-14 |
| FULC | Fulcrum Therapeutics, Inc. Common Stock | 16 | ±0 | Laggard | loss narrowed 11% | — | — | 7 | 2026-04-27 |
| KPRX | Kiora Pharmaceuticals, Inc. Common Stock | 16 | ±0 | Laggard | loss widened 12% | — | — | 76 | 2026-05-08 |
| KROS | Keros Therapeutics, Inc. Common Stock | 16 | ±0 | Laggard | to loss↓ | -100%↓ | <-10,000 bps | 14 | 2026-05-14 |
| NAMS | NewAmsterdam Pharma Company N.V. Ordinary Shares | 16 | ±0 | Laggard | loss widened 18% | +2% | <-10,000 bps | 45 | 2026-05-07 |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | 15 | ±0 | Laggard | loss narrowed 0% | -100% | — | 71 | 2026-05-05 |
| DNLI | Denali Therapeutics Inc. Common Stock | 15 | ±0 | Laggard | loss narrowed 12%↑ | — | — | 79 | 2026-05-07 |
| ENTX | Entera Bio Ltd. Ordinary Shares | 15 | ±0 | Laggard | +17%↑ | -100% | — | 81 | 2026-05-08 |
| ENVB | Enveric Biosciences, Inc. Common Stock | 15 | ±0 | Laggard | loss narrowed 11%↑ | -7% | — | 6 | 2026-05-15 |
| HRTX | Heron Therapeutics, Inc. | 15 | ±0 | Laggard | to loss | -11%↓ | -453 bps | 6 | 2026-05-11 |
| HURA | TuHURA Biosciences, Inc. Common Stock | 15 | ±0 | Laggard | loss narrowed 13% | — | — | 98 | 2026-05-15 |
| LGVN | Longeveron Inc. Common Stock | 15 | -1 | Laggard | loss narrowed 44% | +4%↑ | — | 63 | 2026-05-13 |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 14 | ±0 | Laggard | loss narrowed 12%↑ | -100% | — | 65 | 2026-05-12 |
| MDWD | MediWound Ltd. | 14 | ±0 | Laggard | loss widened 81% | +13% | <-10,000 bps | 35 | 2026-03-05 |
| ROIV | Roivant Sciences Ltd. Common Shares | 14 | -1 | Laggard | to profit | — | — | 90 | 2026-05-20 |
| STOK | Stoke Therapeutics, Inc. Common Stock | 14 | ±0 | Laggard | to loss | -96%↓ | <-10,000 bps | 47 | 2026-05-07 |
| VSTM | Verastem, Inc. | 14 | ±0 | Laggard | loss narrowed 52% | — | — | 39 | 2026-05-07 |
| CNTB | Connect Biopharma Holdings Limited Ordinary Shares | 13 | ±0 | Laggard | loss widened 79%↓ | — | — | 52 | 2026-05-12 |
| DNA | Ginkgo Bioworks Holdings, Inc. | 13 | ±0 | Laggard | loss narrowed 17% | -60% | -1239 bps | 30 | 2026-05-07 |
| OGN | Organon & Co. | 13 | -1 | Laggard | +67% | -4% | -196 bps | 92 | 2026-05-04 |
| PTCT | PTC Therapeutics, Inc. | 13 | ±0 | Laggard | to loss↓ | -77%↓ | -4728 bps | 59 | 2026-05-07 |
| RVMD | Revolution Medicines, Inc. Common StockBiotech & Genomics | 13 | ±0 | Laggard | loss widened 103%↓ | — | — | 90 | 2026-05-06 |
| EDSA | Edesa Biotech, Inc. Common Shares | 12 | ±0 | Laggard | loss widened 63%↓ | -100% | — | 99 | 2026-05-14 |
| LEGN | Legend Biotech Corporation American Depositary Shares | 12 | ±0 | Laggard | to loss | — | — | 61 | 2026-03-10 |
| NRIX | Nurix Therapeutics, Inc. Common stock | 12 | -8 | Laggard | loss widened 56%↓ | -79%↓ | <-10,000 bps | 77 | 2026-07-09 |
| BDTX | Black Diamond Therapeutics, Inc. Common Stock | 11 | ±0 | Laggard | to loss↓ | -100% | — | 22 | 2026-05-07 |
| IMNN | Imunon, Inc. Common Stock | 11 | ±0 | Laggard | loss widened 200% | 0% | — | 12 | 2026-05-12 |
| KRRO | Korro Bio, Inc. Common Stock | 11 | ±0 | Laggard | loss narrowed 32% | -100%↓ | — | 84 | 2026-05-07 |
| MGX | Metagenomi Therapeutics, Inc. Common Stock | 11 | ±0 | Laggard | loss narrowed 10% | -70%↓ | <-10,000 bps | 25 | 2026-05-11 |
| SER | Serina Therapeutics, Inc. | 11 | ±0 | Laggard | loss widened 18%↑ | — | — | 32 | 2026-05-14 |
| XNCR | Xencor, Inc. | 11 | ±0 | Laggard | loss widened 159%↓ | -86%↓ | -8673 bps | 89 | 2026-05-06 |
| ABVX | Abivax SA American Depositary Shares | 10 | ±0 | Laggard | loss widened 81% | -90% | — | 70 | 2026-03-23 |
| AVTX | Avalo Therapeutics, Inc. Common Stock | 10 | ±0 | Laggard | loss narrowed 22% | -100%↓ | — | 74 | 2026-05-13 |
| BNTX | BioNTech SE American Depositary Share | 10 | ±0 | Laggard | loss widened 70% | +4% | -118 bps | 38 | 2026-05-05 |
| LENZ | LENZ Therapeutics, Inc. Common Stock | 10 | ±0 | Laggard | loss widened 149% | — | — | 5 | 2026-05-11 |
| MOLN | Molecular Partners AG American Depositary Shares | 10 | ±0 | Laggard | loss widened 4% | -100% | — | 43 | 2026-03-12 |
| PFE | Pfizer Inc. | 10 | ±0 | Laggard | -10% | +5%↑ | +66 bps | 48 | 2026-05-05 |
| SVRA | Savara Inc. | 10 | ±0 | Laggard | loss widened 25% | -100% | — | 45 | 2026-05-12 |
| VNDA | Vanda Pharmaceuticals Inc. | 10 | ±0 | Laggard | loss widened 64% | +3%↓ | -3765 bps | 25 | 2026-05-07 |
| ZBIO | Zenas BioPharma, Inc. Common Stock | 10 | ±0 | Laggard | loss widened 82% | — | — | 92 | 2026-05-13 |
| FBRX | Forte Biosciences, Inc. Common Stock | 9 | ±0 | Laggard | loss narrowed 9% | -50% | — | 90 | 2026-05-11 |
| LITS | Lite Strategy, Inc. Common Stock | 9 | ±0 | Laggard | loss widened 69% | — | — | 26 | 2026-05-13 |
| ORKA | Oruka Therapeutics, Inc. Common StockBiotech & Genomics | 9 | ±0 | Laggard | loss widened 156%↑ | — | — | 98 | 2026-05-13 |
| PRAX | Praxis Precision Medicines, Inc. Common StockBiotech & Genomics | 9 | +1 | Laggard | loss narrowed 3% | -100% | — | 57 | 2026-05-07 |
| QDEL | QuidelOrtho Corporation Common Stock | 9 | ±0 | Laggard | loss widened 611% | -11% | -3086 bps | 11 | 2026-05-06 |
| SYRE | Spyre Therapeutics, Inc. Common Stock | 9 | ±0 | Laggard | — | — | — | 98 | 2026-05-05 |
| CLDX | Celldex Therapeutics, Inc | 8 | ±0 | Laggard | loss widened 46% | -98% | — | 88 | 2026-05-07 |
| CRVO | CervoMed Inc. Common Stock | 8 | ±0 | Laggard | loss widened 54% | -100%↓ | — | 8 | 2026-05-15 |
| HIND | Vyome Holdings, Inc. Common Stock | 8 | ±0 | Laggard | to loss↓ | -84%↓ | — | 24 | 2026-05-12 |
| IRD | Opus Genetics, Inc. Common Stock | 8 | ±0 | Laggard | loss widened 212% | -51% | >+10,000 bps | 90 | 2026-05-12 |
| LFVN | Lifevantage Corporation Common Stock (Delaware) | 8 | ±0 | Laggard | -58% | -25% | -246 bps | 52 | 2026-05-06 |
| SRPT | Sarepta Therapeutics,, Inc. Common StockBiotech & Genomics | 8 | ±0 | Laggard | to profit | -46%↓ | +316 bps | 30 | 2026-05-06 |
| TIL | Instil Bio, Inc. Common Stock | 8 | ±0 | Laggard | loss narrowed 86% | — | — | 57 | 2026-05-15 |
| VALN | Valneva SE American Depositary Shares | 8 | ±0 | Laggard | loss widened 16% | -10% | -5484 bps | 11 | 2026-03-17 |
| WHWK | Whitehawk Therapeutics, Inc. Common Stock | 8 | ±0 | Laggard | to loss↓ | -100% | — | 87 | 2026-05-07 |
| XBIT | XBiotech Inc | 8 | ±0 | Laggard | loss narrowed 50% | -100% | — | 40 | 2026-05-14 |
| XENE | Xenon Pharmaceuticals Inc | 8 | ±0 | Laggard | loss widened 41% | -100% | — | 94 | 2026-05-07 |
| ARVN | Arvinas, Inc | 7 | ±0 | Laggard | to loss↓ | -92%↓ | <-10,000 bps | 21 | 2026-05-11 |
| CELZ | Creative Medical Technology Holdings, Inc. Common Stock | 7 | ±0 | Laggard | to loss↓ | -100%↓ | — | 10 | 2026-05-08 |
| CTXR | Citius Pharmaceuticals Inc. Common | 7 | ±0 | Laggard | loss narrowed 25%↓ | — | — | 15 | 2026-05-15 |
| CYCN | Cyclerion Therapeutics, Inc. Common Stock | 7 | -1 | Laggard | loss widened 36% | -100%↓ | — | 98 | 2026-05-12 |
| DNTH | Dianthus Therapeutics, Inc. Common Stock | 7 | ±0 | Laggard | loss widened 4% | -79%↑ | — | 97 | 2026-05-05 |
| NGNE | Neurogene, Inc. Common Stock | 7 | ±0 | Laggard | loss widened 29%↓ | — | — | 97 | 2026-05-12 |
| NTHI | NeOnc Technologies Holdings, Inc. Common Stock | 7 | ±0 | Laggard | loss narrowed 82%↑ | -100% | — | 8 | 2026-05-15 |
| SMMT | Summit Therapeutics Inc. Common Stock | 7 | ±0 | Laggard | loss widened 167%↑ | — | — | 30 | 2026-04-30 |
| ARTV | Artiva Biotherapeutics, Inc. Common Stock | 6 | ±0 | Laggard | loss widened 14% | — | — | 97 | 2026-05-08 |
| AYTU | AYTU BioPharma, Inc. Common Stock | 6 | ±0 | Laggard | to loss↓ | -33% | -2122 bps | 30 | 2026-05-13 |
| EBS | Emergent Biosolutions, Inc. | 6 | ±0 | Laggard | -94% | -30%↓ | +1918 bps | 24 | 2026-05-01 |
| PRGO | PERRIGO COMPANY PLC | 6 | ±0 | Laggard | loss widened 999%↓ | -7% | -4185 bps | 23 | 2026-05-06 |
| SCLX | Scilex Holding Company Common Stock | 6 | -1 | Laggard | loss widened 178%↑ | +72% | <-10,000 bps | 21 | 2026-05-20 |
| STRO | Sutro Biopharma, Inc. | 6 | ±0 | Laggard | loss widened 223% | -17% | >+10,000 bps | 95 | 2026-05-14 |
| UNCY | Unicycive Therapeutics, Inc. Common Stock | 6 | ±0 | Laggard | loss widened 198% | -29% | — | 38 | 2026-05-12 |
| VKTX | Viking Therapeutics, IncGLP-1 / ObesityBiotech & Genomics | 6 | ±0 | Laggard | loss widened 234% | — | — | 71 | 2026-04-30 |
| ZYME | Zymeworks Inc. | 6 | ±0 | Laggard | loss widened 97%↓ | -91% | -658 bps | 54 | 2026-05-07 |
| ARCT | Arcturus Therapeutics Holdings Inc. Common Stock | 5 | +1 | Laggard | loss widened 83% | -93%↓ | <-10,000 bps | 30 | 2026-05-07 |
| AZTR | Azitra Inc | 5 | ±0 | Laggard | loss widened 9%↑ | — | — | 9 | 2026-05-13 |
| CAPR | Capricor Therapeutics Inc | 5 | ±0 | Laggard | loss widened 11% | -8% | — | 32 | 2026-05-13 |
| CTMX | CytomX Therapeutics, Inc. | 5 | ±0 | Laggard | to loss | -80% | <-10,000 bps | 34 | 2026-05-07 |
| KYNB | Kyntra Bio, Inc. Common Stock | 5 | -1 | Laggard | to loss↓ | +36% | — | 30 | 2026-05-12 |
| MTNB | Matinas BioPharma Holdings, Inc. | 5 | +1 | Laggard | loss narrowed 9% | — | — | 10 | 2026-05-08 |
| OPK | Opko Health Inc. | 5 | ±0 | Laggard | loss narrowed 30% | -17% | +401 bps | 46 | 2026-04-28 |
| PVLA | Palvella Therapeutics, Inc. Common Stock | 5 | ±0 | Laggard | loss widened 62%↓ | -100% | — | 77 | 2026-05-07 |
| RGNX | REGENXBIO Inc. | 5 | ±0 | Laggard | to loss↓ | -93% | <-10,000 bps | 27 | 2026-05-14 |
| SIGA | SIGA Technologies Inc. | 5 | ±0 | Laggard | loss widened 400% | -11% | -2491 bps | 13 | 2026-05-07 |
| VRAX | Virax Biolabs Group Limited Ordinary Shares | 5 | ±0 | Laggard | loss narrowed 52% | -96% | — | 12 | 2026-07-06 |
| BON | Bon Natural Life Limited Class A Ordinary Shares | 4 | ±0 | Laggard | to loss | -22% | -1655 bps | 21 | 2026-01-23 |
| CATX | Perspective Therapeutics, Inc. | 4 | ±0 | Laggard | loss widened 0% | +11% | — | 75 | 2026-05-11 |
| TCRT | Alaunos Therapeutics, Inc. Common Stock | 4 | ±0 | Laggard | loss narrowed 12% | -100%↓ | — | 25 | 2026-05-15 |
| VERU | Veru Inc. | 4 | ±0 | Laggard | loss widened 140%↑ | -100% | — | 47 | 2026-05-13 |
| AIM | AIM ImmunoTech Inc. | 3 | ±0 | Laggard | loss widened 999% | +38% | — | 4 | 2026-05-15 |
| BMRA | BIOMERICA INC | 3 | ±0 | Laggard | loss widened 633% | -12% | — | 17 | 2026-04-13 |
| BRNS | Barinthus Biotherapeutics plc American Depositary Shares | 3 | ±0 | Laggard | loss narrowed 71%↑ | -100% | — | 33 | 2026-04-30 |
| CLNN | Clene Inc. Common Stock | 3 | ±0 | Laggard | loss widened 667% | -81% | — | 70 | 2026-05-14 |
| COGT | Cogent Biosciences, Inc. Common Stock | 3 | ±0 | Laggard | loss widened 2% | -100% | — | 50 | 2026-05-05 |
| GLUE | Monte Rosa Therapeutics, Inc. Common Stock | 3 | ±0 | Laggard | to loss | -95% | <-10,000 bps | 50 | 2026-05-07 |
| PCSA | Processa Pharmaceuticals, Inc. Common | 3 | +1 | Laggard | loss widened 330% | — | — | 17 | 2026-05-07 |
| SXTC | China SXT Pharmaceuticals, Inc. Class A Ordinary Shares | 3 | -31 | Laggard | loss widened 293% | -35% | — | 3 | 2026-07-01 |
| TRDA | Entrada Therapeutics, Inc. Common Stock | 3 | ±0 | Laggard | loss widened 126% | -96% | — | 17 | 2026-05-07 |
| ALEC | Alector, Inc. Common Stock | 2 | ±0 | Laggard | loss narrowed 49% | -72% | <-10,000 bps | 30 | 2026-05-07 |
| CELU | Celularity Inc. Class A Common Stock | 2 | ±0 | Laggard | loss widened 47% | -77% | <-10,000 bps | 18 | 2026-04-30 |
| GNPX | Genprex, Inc. Common Stock | 2 | ±0 | Laggard | loss widened 146% | — | — | 2 | 2026-05-13 |
| MCRB | Seres Therapeutics, Inc. | 2 | ±0 | Laggard | to loss | — | — | 7 | 2026-05-05 |
| NKTR | Nektar Therapeutics | 2 | ±0 | Laggard | loss widened 658% | +4%↑ | <-10,000 bps | 96 | 2026-05-08 |
| QCLS | Q/C Technologies, Inc. Common Stock | 2 | ±0 | Laggard | loss narrowed 47% | -100% | — | 24 | 2026-05-15 |
| APVO | Aptevo Therapeutics Inc | 1 | ±0 | Laggard | loss widened 46% | -100% | — | 13 | 2026-05-13 |
| BCAB | BioAtla, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -100% | — | 5 | 2026-05-15 |
| BOLT | Bolt Biotherapeutics, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -98% | — | 20 | 2026-05-12 |
| CANF | Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares | 1 | ±0 | Laggard | to loss | -40% | — | 29 | 2026-03-26 |
| DCOY | Decoy Therapeutics Inc. Common Stock | 1 | ±0 | Laggard | loss widened 306% | — | — | 10 | 2026-05-08 |
| ELAB | PMGC Holdings Inc. Common Stock | 1 | ±0 | Laggard | loss widened 287%↑ | — | — | 2 | 2026-05-15 |
| GRI | GRI Bio, Inc. Common Stock | 1 | ±0 | Laggard | loss narrowed 72% | — | — | 4 | 2026-05-13 |
| HELP | Cybin Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -100% | — | 42 | 2026-06-29 |
| IMA | ImageneBio, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 428% | — | — | 39 | 2026-05-07 |
| LYEL | Lyell Immunopharma, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 511% | -71% | — | 15 | 2026-05-06 |
| MBRX | Moleculin Biotech, Inc. | 1 | ±0 | Laggard | loss widened 462% | — | — | 12 | 2026-05-14 |
| NERV | Minerva Neurosciences, Inc | 1 | ±0 | Laggard | loss widened 472% | — | — | 55 | 2026-05-05 |
| NXTC | NextCure, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 379% | -100% | — | 9 | 2026-05-07 |
| NXTS | Nexentis Technologies Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -78% | — | — | 2026-05-14 |
| ONCO | Onconetix, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999% | -79%↓ | — | 1 | 2026-05-13 |
| PTN | Palatin Technologies, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 106% | -56% | — | 12 | 2026-05-13 |
| RNAC | Cartesian Therapeutics, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 115% | -100% | — | 68 | 2026-04-30 |
| SDEV | Stablecoin Development Corporation | 1 | ±0 | Laggard | +135% | — | — | — | 2026-05-15 |
| SNYR | Synergy CHC Corp. Common Stock | 1 | ±0 | Laggard | to loss | -33% | -5730 bps | 2 | 2026-05-14 |
| SPRB | Spruce Biosciences, Inc. Common Stock | 1 | ±0 | Laggard | loss widened 999%↑ | -100% | — | 17 | 2026-05-13 |
Every US common stock and ADR in the universe is ranked on fundamental growth from the numbers companies actually filed with the SEC — no analyst estimates, no forward projections. TickerStance reads EDGAR XBRL company facts directly.
To qualify, a company must have at least six quarters of EPS and revenue history available and the most-recent filing must be no older than 200 days. That gate keeps the rankings grounded in current operating conditions rather than stale data.
Two growth factors are computed: recent year-over-year growth (latest quarter vs the same quarter last year) blended with a three-year trend score. Both factors are percentile-ranked universe-wide so a rank of 90 means the company grows faster than 90% of its peers, regardless of absolute size. The two factor percentiles are then combined into a single 1-99 fundamentals rank.
Operating margin is tracked as context — a company whose margins are expanding while growing revenue is a stronger story than one shrinking margins to buy growth — but margin level is not a direct rank input. Industries, sectors, and themes inherit their rank from the median of their members, so a strong cluster is one where most constituent companies score well, not just a few outliers.
The RS overlap metric shows what share of a cluster's eligible companies sit in the top relative-strength quintile (6M RS rank ≥ 80). When a fundamentally strong group also carries broad price leadership, it has both the earnings story and the institutional sponsorship — the combination that historically precedes sustained outperformance.
Every US common stock and ADR with sufficient SEC filing history gets a 1-99 fundamentals rank: EPS and revenue growth factors are computed from filed XBRL data, percentile-ranked across the universe, and blended. Ranks of 90+ are Leaders, 70-89 Strong, 30-69 Average, below 30 Laggards. Industries, sectors, and themes are then ranked by their members' median rank.
SEC EDGAR XBRL company facts — the numbers companies actually filed. No analyst estimates, no forward guidance, no third-party data vendor.
Sign-aware: a narrowed loss counts as improvement, a widened loss as deterioration, a swing to profit as a turnaround. Conventional percent math misreads losses (a loss shrinking from -$0.12 to -$0.07 is improvement, not "down 42%"), so the table says "loss narrowed 42%" instead of printing a misleading percentage.
The change in a group's median fundamentals rank versus 15 and 30 trading days ago — the classic "improving group" read. Positive means the group is gaining rank. Dashes mean the history window isn't available yet.
Once per US trading day after the close. The as-of date in the header is the snapshot date.